Literature DB >> 8381942

Local production of interleukin-6 during acute rejection in human renal allografts.

M H Raasveld1, J J Weening, J M Kerst, S Surachno, R J ten Berge.   

Abstract

Interleukin-6 is involved in T-cell activation and possibly plays a role in the pathogenesis of acute rejection of transplanted organs. This is indicated by elevated levels of interleukin-6 in serum and urine of renal allograft recipients, and elevated amounts of mRNA for interleukin-6 in all different cell types of the renal allograft during acute rejection episodes. However, transplant recipients receive immunosuppressive drug therapy which may inhibit production of interleukin-6 at the post-transcriptional level. Therefore, the aim of the present study was to detect interleukin-6 in biopsies taken during acute renal allograft rejection by immunohistochemical staining. In addition, serial sections were stained with cellular markers to identify interleukin-6-producing cells. In biopsies taken during acute rejection (n = 7), interleukin-6 could be detected in tubular cells (7/7) mesangial cells (3/7) and monocytes/macrophages (4/7), but not in vascular endothelium or lymphocytes. In control biopsies weak interleukin-6 staining of tubular cells only was present or there was no staining at all. We conclude that interleukin-6 is actually produced in the renal allograft during acute rejection, and that elevated urinary interleukin-6 levels during acute rejection seem to originate mainly from synthesis of interleukin-6 by renal tubular cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8381942     DOI: 10.1093/oxfordjournals.ndt.a092278

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  3 in total

1.  Interleukin-6 stimulates epithelial sodium channels in mouse cortical collecting duct cells.

Authors:  Ke Li; Dehuang Guo; Haidong Zhu; Kathleen S Hering-Smith; L Lee Hamm; Jingping Ouyang; Yanbin Dong
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-05-26       Impact factor: 3.619

2.  Efficacy of tocilizumab, a humanized neutralizing antibody against interleukin-6 receptor, in progressive renal injury associated with Castleman's disease.

Authors:  Akito Maeshima; Masao Nakasatomi; Daizo Henmi; Shin Yamashita; Yoriaki Kaneko; Takashi Kuroiwa; Keiju Hiromura; Yoshihisa Nojima
Journal:  CEN Case Rep       Date:  2012-03-17

Review 3.  IL-6 Directed Therapy in Transplantation.

Authors:  Cynthia L Miller; Joren C Madsen
Journal:  Curr Transplant Rep       Date:  2021-06-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.